CHUV becomes Switzerland's first hospital approved to produce medication from fecal bacteria, marking a breakthrough in treating severe intestinal infections.
"The treatment of such infections with a faecal microbiota transplant has proven to be significantly more effective than conventional treatment with antibiotics"
In a groundbreaking development for Swiss healthcare, the University Hospital of Canton Vaud (CHUV) in Lausanne has achieved a significant milestone by becoming Switzerland's first hospital authorized to produce medication derived from fecal bacteria. This pioneering achievement, approved by Swissmedic, positions Lausanne at the forefront of innovative medical treatments in Switzerland. The authorization marks a crucial step forward in treating severe intestinal infections, particularly those caused by Clostridium difficile.
The innovative treatment, known as fecal microbiota transplantation (FMT), involves a sophisticated process of transplanting healthy intestinal bacteria from carefully screened donors to patients suffering from severe intestinal infections. This method represents a significant advancement over traditional antibiotic treatments, particularly in addressing Clostridium difficile infections, which often result in severe diarrhea and have historically shown high relapse rates. The treatment is administered through specially prepared pills containing beneficial bacteria isolated from donor stool.
CHUV maintains exceptionally high standards in its donor selection process, with only approximately 10% of potential donors meeting the stringent criteria for acceptance. This rigorous screening ensures the highest safety standards for the treatment. The production process involves careful collection of stool samples from approved donors, followed by sophisticated laboratory procedures to isolate healthy bacteria. This meticulous approach to donor selection and production demonstrates Switzerland's commitment to maintaining the highest standards in medical treatments.
The effectiveness of this innovative treatment has been remarkable, with cure rates reaching up to 95% compared to just 30% with traditional antibiotic treatments alone. This significant improvement in treatment outcomes represents a major advancement in managing severe intestinal infections. While the treatment is currently not covered by Swiss health insurance, CHUV has submitted an application to the Federal Office of Public Health for coverage consideration. This development could potentially revolutionize the treatment of intestinal infections across Switzerland and serve as a model for other European healthcare institutions.